I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
- Stocks slip off record highs ahead of earnings, U.S. data
- Microsoft (MSFT) Near Deal to Acquire Nuance (NUAN) - Report
- Dollar bounces higher as traders brace for inflation data
Conference Call Scheduled for March 29 at 8:00 a.m. ET with Pre-Registration Required
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SHANGHAI and GAITHERSBURG, Md., March 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the full year ended December 31, 2020 before the market opens on Monday, March 29, 2021, and host a conference call to discuss the results and provide a corporate update at 8:00 a.m. ET.
Conference Call and Webcast Information
I-Mab will host a live conference call and webcast on March 29, 2021 at 8:00 a.m. ET. Participants must register in advance of the conference call. Details are as follows:
Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.
A webcast replay will be archived on the Company's website for one year after the conclusion of the call at http://ir.i-mabbiopharma.com.
A telephone replay will be available approximately two hours after the conclusion of the call. To access the replay, please call +1-855-452-5696 (U.S.), +61-2-8199-0299 (International), 400-632-2162 (Mainland China), or 800-963-117 (Hong Kong). The conference ID number for the replay is 4848159.
I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter and WeChat.
For more information, please contact:
Jielun Zhu, Chief Financial OfficerE-mail: email@example.comOffice line: +86 21 6057 8000
Gigi Feng, Chief Communications OfficerE-mail: firstname.lastname@example.orgOffice line: +86 21 6057 5785
The Piacente Group, Inc.Emilie WuE-mail: email@example.comOffice line: +86 21 6039 8363
View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-to-report-financial-results-for-the-full-year-2020-and-provide-corporate-update-on-march-29-2021-301239583.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- InMode Ltd. (INMD) Expects Q1 Revenue Between $65.0-$65.4M, EPS Between $0.65-$0.67
- DoControl Launches with $13.35M in Funding to Automate SaaS Data Access Controls
- Sterling Bancorp to Announce First Quarter 2021 Results